Skip to content
Open access · US-GOV via ClinicalTrials.gov Clinical trial

Erlotinib (Tarceva®) in Routine Clinical Practice in Patients With Advanced Non Small Cell Lung Cancer (NSCLC) After Failure of at Least One Prior Chemotherapy Regimen With Focus on the Elderly Patient.

Authors not listed

Hoffmann-La Roche · 2011

Abstract

This prospective observational study will evaluate the efficacy and safety of Tarceva (erlotinib) in elderly patients with advanced non-small cell lung cancer (NSCLC) after failure of at least one prior chemotherapy regimen. Data of patients treated with Tarceva in routine clinical practice will be collected for 1 year.

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source
ClinicalTrials.gov
Canonical
link ↗
Fetched
2026-11-06 MST

Cite this

APA
Anonymous. (2011). Erlotinib (Tarceva®) in Routine Clinical Practice in Patients With Advanced Non Small Cell Lung Cancer (NSCLC) After Failure of at Least One Prior Chemotherapy Regimen With Focus on the Elderly Patient. <em>Hoffmann-La Roche</em>. https://clinicaltrials.gov/study/NCT01535729
Vancouver
Anonymous. Erlotinib (Tarceva®) in Routine Clinical Practice in Patients With Advanced Non Small Cell Lung Cancer (NSCLC) After Failure of at Least One Prior Chemotherapy Regimen With Focus on the Elderly Patient. Hoffmann-La Roche. 2011.
BibTeX
@misc{anon2011Erloti, title = {Erlotinib (Tarceva®) in Routine Clinical Practice in Patients With Advanced Non Small Cell Lung Cancer (NSCLC) After Failure of at Least One Prior Chemotherapy Regimen With Focus on the Elderly Patient.}, author = {Anonymous}, journal = {Hoffmann-La Roche}, year = {2011}, }

Research neighborhood

References, citing works, and semantically nearest findings. Click a node to open it.

Related findings